Immunofluorometric assay of pepsinogen C and preliminary clinical applications

E. P. Diamandis, S. Nadkarni, B. Bhaumik, A. Abdelrahman, D. N. Melegos, G. Borchert, M. H. Black, M. Alonso, A. Salas, J. R. De los Toyos, A. Sampedro, C. Lopez-Otin

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

We developed mouse monoclonal antibodies (Abs) against pepsinogen C with highly purified antigen isolated from gastric mucosa. The Abs were used to construct a two-site sandwich-type assay for pepsinogen C with time-resolved fluorometry as a detection technique. The assay has a detection limit of 0.1 μg/L and is precise (within-run and day-to-day CVs <11%). We used this assay to measure pepsinogen C in seminal plasma, breast cyst fluid, amniotic fluid, male and female serum, serum from patients with prostate cancer, urine, breast tumor cytosolic extracts, breast milk, and cerebrospinal fluid. Highest pepsinogen C concentrations were in seminal plasma, followed by breast cyst fluid and amniotic fluid. We found no correlation between prostate-specific antigen concentrations and concentrations of pepsinogen C in serum of prostate cancer patients, and concluded that this marker is not useful for either diagnosing or monitoring prostatic carcinoma. The availability of a highly sensitive, reliable, and convenient method for quantifying pepsinogen C will allow investigations into the possible diagnostic value of this analyte in various clinical conditions, including benign breast diseases, breast cancer, fertility and pregnancy.

Original languageEnglish
Pages (from-to)1365-1371
Number of pages7
JournalClinical Chemistry
Volume43
Issue number8
Publication statusPublished - 1997

Fingerprint

Pepsinogen C
Fluoroimmunoassay
Assays
Breast Cyst
Cyst Fluid
Fluids
Amniotic Fluid
Breast Neoplasms
Semen
Prostatic Neoplasms
Serum
Cerebrospinal fluid
Plasmas
Fluorometry
Breast Diseases
Human Milk
Prostate-Specific Antigen
Gastric Mucosa
Fertility
Cerebrospinal Fluid

Keywords

  • Amniotic fluid
  • Androgen- regulated genes
  • Breast cancer
  • Prognostic markers
  • Proteases

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Diamandis, E. P., Nadkarni, S., Bhaumik, B., Abdelrahman, A., Melegos, D. N., Borchert, G., ... Lopez-Otin, C. (1997). Immunofluorometric assay of pepsinogen C and preliminary clinical applications. Clinical Chemistry, 43(8), 1365-1371.

Immunofluorometric assay of pepsinogen C and preliminary clinical applications. / Diamandis, E. P.; Nadkarni, S.; Bhaumik, B.; Abdelrahman, A.; Melegos, D. N.; Borchert, G.; Black, M. H.; Alonso, M.; Salas, A.; De los Toyos, J. R.; Sampedro, A.; Lopez-Otin, C.

In: Clinical Chemistry, Vol. 43, No. 8, 1997, p. 1365-1371.

Research output: Contribution to journalArticle

Diamandis, EP, Nadkarni, S, Bhaumik, B, Abdelrahman, A, Melegos, DN, Borchert, G, Black, MH, Alonso, M, Salas, A, De los Toyos, JR, Sampedro, A & Lopez-Otin, C 1997, 'Immunofluorometric assay of pepsinogen C and preliminary clinical applications', Clinical Chemistry, vol. 43, no. 8, pp. 1365-1371.
Diamandis EP, Nadkarni S, Bhaumik B, Abdelrahman A, Melegos DN, Borchert G et al. Immunofluorometric assay of pepsinogen C and preliminary clinical applications. Clinical Chemistry. 1997;43(8):1365-1371.
Diamandis, E. P. ; Nadkarni, S. ; Bhaumik, B. ; Abdelrahman, A. ; Melegos, D. N. ; Borchert, G. ; Black, M. H. ; Alonso, M. ; Salas, A. ; De los Toyos, J. R. ; Sampedro, A. ; Lopez-Otin, C. / Immunofluorometric assay of pepsinogen C and preliminary clinical applications. In: Clinical Chemistry. 1997 ; Vol. 43, No. 8. pp. 1365-1371.
@article{506e413bcfe7447aa23bf6f53f3d5a52,
title = "Immunofluorometric assay of pepsinogen C and preliminary clinical applications",
abstract = "We developed mouse monoclonal antibodies (Abs) against pepsinogen C with highly purified antigen isolated from gastric mucosa. The Abs were used to construct a two-site sandwich-type assay for pepsinogen C with time-resolved fluorometry as a detection technique. The assay has a detection limit of 0.1 μg/L and is precise (within-run and day-to-day CVs <11{\%}). We used this assay to measure pepsinogen C in seminal plasma, breast cyst fluid, amniotic fluid, male and female serum, serum from patients with prostate cancer, urine, breast tumor cytosolic extracts, breast milk, and cerebrospinal fluid. Highest pepsinogen C concentrations were in seminal plasma, followed by breast cyst fluid and amniotic fluid. We found no correlation between prostate-specific antigen concentrations and concentrations of pepsinogen C in serum of prostate cancer patients, and concluded that this marker is not useful for either diagnosing or monitoring prostatic carcinoma. The availability of a highly sensitive, reliable, and convenient method for quantifying pepsinogen C will allow investigations into the possible diagnostic value of this analyte in various clinical conditions, including benign breast diseases, breast cancer, fertility and pregnancy.",
keywords = "Amniotic fluid, Androgen- regulated genes, Breast cancer, Prognostic markers, Proteases",
author = "Diamandis, {E. P.} and S. Nadkarni and B. Bhaumik and A. Abdelrahman and Melegos, {D. N.} and G. Borchert and Black, {M. H.} and M. Alonso and A. Salas and {De los Toyos}, {J. R.} and A. Sampedro and C. Lopez-Otin",
year = "1997",
language = "English",
volume = "43",
pages = "1365--1371",
journal = "Clinical Chemistry",
issn = "0009-9147",
publisher = "American Association for Clinical Chemistry Inc.",
number = "8",

}

TY - JOUR

T1 - Immunofluorometric assay of pepsinogen C and preliminary clinical applications

AU - Diamandis, E. P.

AU - Nadkarni, S.

AU - Bhaumik, B.

AU - Abdelrahman, A.

AU - Melegos, D. N.

AU - Borchert, G.

AU - Black, M. H.

AU - Alonso, M.

AU - Salas, A.

AU - De los Toyos, J. R.

AU - Sampedro, A.

AU - Lopez-Otin, C.

PY - 1997

Y1 - 1997

N2 - We developed mouse monoclonal antibodies (Abs) against pepsinogen C with highly purified antigen isolated from gastric mucosa. The Abs were used to construct a two-site sandwich-type assay for pepsinogen C with time-resolved fluorometry as a detection technique. The assay has a detection limit of 0.1 μg/L and is precise (within-run and day-to-day CVs <11%). We used this assay to measure pepsinogen C in seminal plasma, breast cyst fluid, amniotic fluid, male and female serum, serum from patients with prostate cancer, urine, breast tumor cytosolic extracts, breast milk, and cerebrospinal fluid. Highest pepsinogen C concentrations were in seminal plasma, followed by breast cyst fluid and amniotic fluid. We found no correlation between prostate-specific antigen concentrations and concentrations of pepsinogen C in serum of prostate cancer patients, and concluded that this marker is not useful for either diagnosing or monitoring prostatic carcinoma. The availability of a highly sensitive, reliable, and convenient method for quantifying pepsinogen C will allow investigations into the possible diagnostic value of this analyte in various clinical conditions, including benign breast diseases, breast cancer, fertility and pregnancy.

AB - We developed mouse monoclonal antibodies (Abs) against pepsinogen C with highly purified antigen isolated from gastric mucosa. The Abs were used to construct a two-site sandwich-type assay for pepsinogen C with time-resolved fluorometry as a detection technique. The assay has a detection limit of 0.1 μg/L and is precise (within-run and day-to-day CVs <11%). We used this assay to measure pepsinogen C in seminal plasma, breast cyst fluid, amniotic fluid, male and female serum, serum from patients with prostate cancer, urine, breast tumor cytosolic extracts, breast milk, and cerebrospinal fluid. Highest pepsinogen C concentrations were in seminal plasma, followed by breast cyst fluid and amniotic fluid. We found no correlation between prostate-specific antigen concentrations and concentrations of pepsinogen C in serum of prostate cancer patients, and concluded that this marker is not useful for either diagnosing or monitoring prostatic carcinoma. The availability of a highly sensitive, reliable, and convenient method for quantifying pepsinogen C will allow investigations into the possible diagnostic value of this analyte in various clinical conditions, including benign breast diseases, breast cancer, fertility and pregnancy.

KW - Amniotic fluid

KW - Androgen- regulated genes

KW - Breast cancer

KW - Prognostic markers

KW - Proteases

UR - http://www.scopus.com/inward/record.url?scp=0030855626&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030855626&partnerID=8YFLogxK

M3 - Article

VL - 43

SP - 1365

EP - 1371

JO - Clinical Chemistry

JF - Clinical Chemistry

SN - 0009-9147

IS - 8

ER -